Cargando…

Guidelines on the Clinical Evaluation of Medicinal Products for Treatment of Dyslipidemia

Detalles Bibliográficos
Autores principales:	Yamashita, Shizuya, Masuda, Daisaku, Akishita, Masahiro, Arai, Hidenori, Asada, Yujiro, Dobashi, Kazushige, Egashira, Kensuke, Harada-Shiba, Mariko, Hirata, Kenichi, Ishibashi, Shun, Kajinami, Kouji, Kinoshita, Makoto, Kozaki, Koichi, Kuzuya, Masafumi, Ogura, Masatsune, Okamura, Tomonori, Sato, Kayoko, Shimano, Hitoshi, Tsukamoto, Kazuhisa, Yokode, Masayuki, Yokote, Koutaro, Yoshida, Masayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803830/ https://www.ncbi.nlm.nih.gov/pubmed/32863291 http://dx.doi.org/10.5551/jat.CR004

Ejemplares similares

Guidance for Pediatric Familial Hypercholesterolemia 2017
por: Harada-Shiba, Mariko, et al.
Publicado: (2018)

Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017
por: Harada-Shiba, Mariko, et al.
Publicado: (2018)

Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022
por: Harada-Shiba, Mariko, et al.
Publicado: (2023)

Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate
por: Yamashita, Shizuya, et al.
Publicado: (2021)

Time to consider an Asian guideline for management of dyslipidemia?
por: Yokote, Koutaro, et al.
Publicado: (2012)

Updates on dyslipidemia in patients with diabetes
por: Ide, Shintaro, et al.
Publicado: (2023)

Diagnosis and Management of Sitosterolemia 2021
por: Tada, Hayato, et al.
Publicado: (2021)

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017
por: Kinoshita, Makoto, et al.
Publicado: (2018)

Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
por: Arai, Hidenori, et al.
Publicado: (2018)

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment
por: Yokote, Koutaro, et al.
Publicado: (2019)

Cultural Barriers in the Treatment of Dyslipidemia: A Survey of Japanese Physician Attitudes
por: Yamashita, Shizuya, et al.
Publicado: (2019)

Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2019)

Statement for Appropriate Clinical Use of PCSK9 Inhibitors
por: Nohara, Atsushi, et al.
Publicado: (2018)

Factors Associated with Carotid Atherosclerosis and Achilles Tendon Thickness in Japanese Patients with Familial Hypercholesterolemia: A Subanalysis of the Familial Hypercholesterolemia Expert Forum (FAME) Study
por: Ogura, Masatsune, et al.
Publicado: (2022)

Prospective Registry Study of Primary Dyslipidemia (PROLIPID): Rationale and Study Design
por: Tada, Hayato, et al.
Publicado: (2022)

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2020)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

Current Diagnosis and Management of Tangier Disease
por: Koseki, Masahiro, et al.
Publicado: (2021)

Effects of a novel selective peroxisome proliferator‐activated receptor‐α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance
por: Matsuba, Ikuro, et al.
Publicado: (2018)

Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination
por: Yamashita, Shizuya, et al.
Publicado: (2019)

Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials
por: Yokote, Koutaro, et al.
Publicado: (2021)

Real-World Data to Identify Hypercholesterolemia Patients on Suboptimal Statin Therapy
por: Kajinami, Kouji, et al.
Publicado: (2019)

Homozygous Familial Hypercholesterolemia
por: Nohara, Atsushi, et al.
Publicado: (2021)

Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022
por: Harada-Shiba, Mariko, et al.
Publicado: (2023)

Current Status of Familial LCAT Deficiency in Japan
por: Kuroda, Masayuki, et al.
Publicado: (2021)

Effects of Phenotypic and Genotypic Factors on the Lipid Responses to Niacin in Chinese Patients With Dyslipidemia
por: Hu, Miao, et al.
Publicado: (2015)

Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study
por: Yamashita, Shizuya, et al.
Publicado: (2022)

A Case of Myopericarditis After the Second Dose of mRNA COVID-19 Vaccine in a Patient With a History of Myopericarditis
por: Fujibayashi, Kosuke, et al.
Publicado: (2022)

Statin Intolerance Clinical Guide 2018
por: Kajinami, Kouji, et al.
Publicado: (2020)

Helicobacter cinaedi infection in patients with diabetes: a case report
por: Ishibashi, Ryoichi, et al.
Publicado: (2015)

Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study
por: Naito, Ryo, et al.
Publicado: (2022)

The increase in prescriptions of bisphosphonates and the incidence proportion of osteonecrosis of the jaw after risk communication activities in Japan: a hospital-based cohort study†
por: Sumi, Eriko, et al.
Publicado: (2014)

Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52‐week data from the PROVIDE study
por: Araki, Eiichi, et al.
Publicado: (2019)

A survey of attitudes toward clinical research among physicians at Kyoto University Hospital
por: Sumi, Eriko, et al.
Publicado: (2009)

Development of Antisense Drugs for Dyslipidemia
por: Yamamoto, Tsuyoshi, et al.
Publicado: (2016)

New perspective on type 2 diabetes, dyslipidemia and non‐alcoholic fatty liver disease
por: Matsuzaka, Takashi, et al.
Publicado: (2020)

Enhanced Intestinal Absorption of Cholesterol along with Increased Chylomicron Remnants for De novo Progression of Coronary Stenosis
por: Masuda, Daisaku, et al.
Publicado: (2017)

Postprandial Hyperlipidemia and Remnant Lipoproteins
por: Masuda, Daisaku, et al.
Publicado: (2017)

Postprandial Glucose and Triglyceride Increases Along with the Endothelial Malfunction were Attenuated by the Administration of SGLT2 Inhibitor, Empagliflozin
por: Masuda, Daisaku, et al.
Publicado: (2020)

Serum HDL-Cholesterol Level Does Not Influence Cardiovascular Event Rate under Sufficient Lowering of LDL-Cholesterol by Pitavatatin in Patients with Stable Coronary Artery Disease
por: Masuda, Daisaku, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pdqq51beqc7gkgq3e6v1lmo669